MGMT and central nervous system cancer: While none of those exact cutoffs were statistically significant (see Supplementary Table S5 for details), there were clearly different slopes of MGMT promoter methylation positivity curves as a function of VAF within each glioma subtype (Fig. 2F J, and 2 N).